Dr Roy Bicknell
Dr Bicknell is head of the Cancer Research UK Angiogenesis Laboratory at the Institute of Molecular Medicine of Oxford University.

"We can’t do everything alone because we’re a basic research laboratory. We work with the CRT Development Laboratory to take a potential therapy further and then, if it still looks promising, to partner with industry."

"CRT are a respected organisation recognised as the leading intellectual property company for cancer in Europe. For CRT to contact a company carries a lot more weight than if I were to do so directly."

Professor Joyce Taylor-Papadimitriou
Professor Taylor-Papadimitriou is Principal Scientist of the Cancer Research UK Breast Cancer Biology Group and Honorary Professor of Oncology at Guy’s Hospital, London.

"We couldn’t have pursued these developments without CRT. It’s quite rare to see something you have discovered generate real money. It will be even more satisfying when any of the products are shown to have some impact on patient management."

Professor Anton Berns
Professor Anton Berns is Director of Research at the Netherlands Cancer Institute.

"The relationship with CRT has helped us enormously in evaluating and securing our intellectual property. In addition, CRT’s worldwide contacts with the biotechnology and pharmaceutical industry make it possible to exploit our discoveries in such a way that it will benefit cancer patients. We are looking forward to working with them in the years to come."